4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-04-24
DOI
10.3389/fimmu.2020.00577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
- (2020) Min Yang et al. OncoImmunology
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up
- (2019) Britt Roosenboom et al. INFLAMMATORY BOWEL DISEASES
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Principles of adoptive T cell therapy in cancer
- (2018) Özcan Met et al. Seminars in Immunopathology
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells
- (2017) Michel Enamorado et al. Nature Communications
- Induction of resident memory T cells enhances the efficacy of cancer vaccine
- (2017) Mevyn Nizard et al. Nature Communications
- Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites
- (2017) Brahma V. Kumar et al. Cell Reports
- Tissue-resident lymphocytes: sentinel of the transformed tissue
- (2017) Saïda Dadi et al. Journal for ImmunoTherapy of Cancer
- Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
- (2017) Rahima Jamal et al. Journal for ImmunoTherapy of Cancer
- TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment
- (2016) Marie Boutet et al. CANCER RESEARCH
- CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
- (2016) T. Ahrends et al. CANCER RESEARCH
- CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
- (2016) Hagma H. Workel et al. EUROPEAN JOURNAL OF CANCER
- Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
- (2016) Pleun Hombrink et al. NATURE IMMUNOLOGY
- CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
- (2016) Fenne L. Komdeur et al. Oncotarget
- IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses
- (2015) Xuefeng Wang et al. CANCER CELL
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder
- (2015) Bo Wang et al. JOURNAL OF UROLOGY
- PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
- (2015) J. R. Webb et al. Cancer Immunology Research
- Intrinsically de-sialylated CD103+ CD8 T cells mediate beneficial anti-glioma immune responses
- (2014) Emmanuel Jouanneau et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-specific IL-9–producing CD8+Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers
- (2014) Yong Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
- (2014) S. Chen et al. Cancer Immunology Research
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
- (2013) J. R. Webb et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling Controls the Formation and Maintenance of Gut-Resident Memory T Cells by Regulating Migration and Retention
- (2013) Nu Zhang et al. IMMUNITY
- Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
- (2013) Michael A. Curran et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lung-resident memory CD8 T cells (TRM ) are indispensable for optimal cross-protection against pulmonary virus infection
- (2013) Tao Wu et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Fiji: an open-source platform for biological-image analysis
- (2012) Johannes Schindelin et al. NATURE METHODS
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started